Literature DB >> 18823457

Establishment of a porcine right ventricular infarction model for cardioprotective actions of xenon and isoflurane.

M Hein1, A B Roehl, J H Baumert, B Bantes, C Bleilevens, N Bernstein, P Steendijk, R Rossaint.   

Abstract

BACKGROUND: Right ventricular (RV) function is an important determinant of post-operative outcome. Consequences of RV infarction might be limited by pre-conditioning with volatile anesthetic drugs. Therefore, we used a porcine model of RV ischemia and reperfusion (IR) injury to study the influence of isoflurane and xenon on the extent and degree of myocardial injury.
METHODS: IR injury was induced by a 90-min ligation of the distal right coronary artery and 120-min reperfusion in thiopental anesthetized pigs. A control group (n=12) was compared with two groups, which received either 0.55 minimum alveolar concentration (MAC) isoflurane (n=10) or xenon (n=12) starting 60 min before ischemia. Myocardial injury was described by three criteria: the infarct size related to area at risk (IS/AAR), the infiltration of neutrophils as determined by myeloperoxidase (MPO) activity, and the plasma levels of tumor necrosis factor alpha (TNFalpha), interleukin 6 (IL-6), myoglobin and troponin-T (TnT).
RESULTS: IS/AAR was reduced from 58.3+/-6.2% in the control group to 41.8+/-7.8% after isoflurane and 42.7+/-8.5% after xenon pre-treatment, which equals an absolute reduction of 16.5% [95% confidence interval (CI): 10.9-22.1] and 15.5% (95% CI: 10.1-20.9). The maximum increase of TnT could be observed within the xenon group. Both treatment groups were characterized by lower MPO activity, in the infarct and periinfarct region and lower plasma concentrations of TNFalpha and IL-6.
CONCLUSIONS: It could be demonstrated for the first time in a model of RV infarction that the continuous application of isoflurane or xenon before, during and after ischemia reduced the extent (size) and severity (inflammation) of myocardial injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18823457     DOI: 10.1111/j.1399-6576.2008.01757.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  9 in total

Review 1.  [Current developments in xenon research. Importance for anesthesia and intensive care medicine].

Authors:  A Brücken; M Coburn; S Rex; R Rossaint; M Fries
Journal:  Anaesthesist       Date:  2010-10       Impact factor: 1.041

2.  Protective effects of adenosine in rabbit sinoatrial node ischemia-reperfusion model in vivo: control of arrhythmia by hyperpolarization-activated cyclic nucleotide-gated (HCN)4 channels.

Authors:  Feng-Xu Yu; Jian-Juan Ke; Yong Fu; Bin Liao; Ying-Kang Shi
Journal:  Mol Biol Rep       Date:  2010-09-15       Impact factor: 2.316

3.  A porcine model for acute ischaemic right ventricular dysfunction.

Authors:  Pernille Haraldsen; Sandra Lindstedt; Carsten Metzsch; Lars Algotsson; Richard Ingemansson
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-10-02

4.  Comparison of 3 methods to induce acute pulmonary hypertension in pigs.

Authors:  Anna B Roehl; Paul Steendijk; Jan H Baumert; Joerg Schnoor; Rolf Rossaint; Marc Hein
Journal:  Comp Med       Date:  2009-06       Impact factor: 0.982

5.  Xenon pretreatment may prevent early memory decline after isoflurane anesthesia and surgery in mice.

Authors:  Marcela P Vizcaychipi; Dafydd G Lloyd; Yanjie Wan; Mark G Palazzo; Mervyn Maze; Daqing Ma
Journal:  PLoS One       Date:  2011-11-03       Impact factor: 3.240

6.  Antiapoptotic activity of argon and xenon.

Authors:  Sabrina Spaggiari; Oliver Kepp; Santiago Rello-Varona; Kariman Chaba; Sandy Adjemian; Jan Pype; Lorenzo Galluzzi; Marc Lemaire; Guido Kroemer
Journal:  Cell Cycle       Date:  2013-07-16       Impact factor: 4.534

7.  Xenon protects left ventricular diastolic function during acute ischemia, less than ischemic preconditioning.

Authors:  Jan-H Baumert; Anna B Roehl; Sandra Funcke; Marc Hein
Journal:  Med Gas Res       Date:  2016-10-14

Review 8.  Cardioprotection in right heart failure.

Authors:  Kerstin Boengler; Klaus-Dieter Schlüter; Ralph Theo Schermuly; Rainer Schulz
Journal:  Br J Pharmacol       Date:  2020-03-09       Impact factor: 8.739

Review 9.  Update of the organoprotective properties of xenon and argon: from bench to beside.

Authors:  Roehl Anna; Rossaint Rolf; Coburn Mark
Journal:  Intensive Care Med Exp       Date:  2020-02-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.